NCT07419269 Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation
| NCT ID | NCT07419269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Alveolar Bone Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2025-04-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine whether jawbone augmentations using allogeneic and autogenous bone blocks lead to comparable three-dimensional clinical and radiological outcomes. In addition, the study seeks to investigate whether there are differences regarding safety, biocompatibility, complications, and PROMs. Furthermore, it aims to clarify whether differences exist between the two groups with respect to implant condition (one year after implantation and during annual follow-ups for up to five years).
Eligibility Criteria
INCLUSION CRITERIA * 1-4 missing teeth that need to be replaced with dental implants * Bone ridge width insufficient for dental implant placement; \<5 mm of width as measured in a cone beam computed tomography at the ideal prosthetic position * Medically healthy with no known allergies to antibiotics * Non-smoker or light smoker (\< 10) or previous smoker who had quit for 5 years or more * Periodontal health, as confirmed by clinical examination (Full mouth bleeding score and full mouth plaque score \< 25%) and at least one neighboring natural tooth to the defect site(s) * Age of 18 or above EXCLUSION CRITERIA * All contraindications against implant treatment or augmentative procedures (e.g., advanced systemic diseases, corticosteroid medication, immunodeficiency, pregnancy, intention to become pregnant, breastfeeding, lack of safe contraception) * Treatments or diseases that may have an effect on bone turnover or the bone itself or non-mineralized tissue metabolism (e.g., bisphosphonates or local radiotherapy, skeletal immaturity) * Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone diseases * Any active malignancy or patient undergoing treatment for a malignancy Study protocol: IndiALLO Version 4/19.03.2025 Page 9 von 32 * Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to class of drugs or the investigational product * Persistent compartment syndrome or neurovascular residua of compartment syndrome
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07419269 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alveolar Bone Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07419269 currently recruiting?
Yes, NCT07419269 is actively recruiting participants. Contact the research team at mi.payer@medunigraz.at for enrollment information.
Where is the NCT07419269 trial being conducted?
This trial is being conducted at Graz, Austria.
Who is sponsoring the NCT07419269 clinical trial?
NCT07419269 is sponsored by Medical University of Graz. The trial plans to enroll 26 participants.